Form 4: Pacira BioSciences Chief Medical Officer Sells Shares to Cover Tax Obligations and Under Pre-Arranged Trading Plan
SEC Form 4 Filing
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold shares to cover tax obligations and under a pre-arranged trading plan.
Summary
- Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, sold 371 shares of common stock on January 2, 2025, at a price of $18.33 per share to cover tax obligations related to vesting restricted stock units.
- He also sold 879 shares on January 6, 2025, at $18.40 per share under a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Slonin beneficially owns 93,443.511 shares of Pacira BioSciences common stock.
- The transactions included 386.765 shares acquired under the company's employee stock purchase plan in December 2024.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity, which is neither positive nor negative. The sales are expected and do not indicate any change in the company's outlook.
Industry Context
This is a routine filing related to insider trading activity and is common for executives who receive stock-based compensation. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without being accused of trading on non-public information.
- Similar filings are regularly made by executives at companies like Amgen, Regeneron, and Biogen when they sell shares for tax purposes or under pre-arranged plans.
Stakeholder Impact
- The stock sales by the Chief Medical Officer may have a minor impact on the stock price, but are unlikely to be significant given the relatively small number of shares sold and the pre-arranged nature of the sales.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Jonathan Slonin sold 371 shares to cover tax obligations. |
| 01/06/2025 | Jonathan Slonin sold 879 shares under a pre-arranged trading plan. |
Keywords
Pacira BioSciences, insider trading, Form 4, Jonathan Slonin, stock sale, Rule 10b5-1, tax obligations, employee stock purchase plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.